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Materials and Methods 
Strains, medium and growth conditions. Primers, strains and plasmids are listed in 
Table S2 (31-33). All expression constructs were derivatives of the IPTG inducible 
plasmid pET-20b(+) (Novagen). The gene for MFORT_14352 lacking the N-terminal 29 
amino acids (podA30-162) was PCR amplified from Mycobacterium fortuitum ATCC 6841 
using primers listed in Table S2 and first placed into the NdeI and PstI sites of plasmid 
pSD5 (34) to verify expression of a His tag construct in a vector we used previously for 
podA expression in Rhodococcus sp. JVH1 (9). Primers encoded both a TEV protease 
cleavage site and a 6x-His tag on the C-terminus. Activity was observed in the 
Escherichia coli cloning strain, so we transferred the podA30-162 construct to an E. coli 
expression vector for further analysis. PCR product was digested with NdeI and NotI and 
ligated into digested pET-20b(+) before transfer into E. coli BL21(DE3) cells by 
electroporation (33). Mutant proteins were generated by PCR amplifying pET-20b(+) 
containing podA30-162 with primers encoding the relevant mutation (Table S2). Product 
was cut with DpnI to remove WT vector, phosphorylated with T4 polynucleotide kinase, 
and ligated to generate a circular mutant protein expression construct. For D72N and 
Y156F mutants, DNA fragments encoding the mutation were synthesized (Integrated 
DNA Technologies) and cloned into pET-20b(+) as for the wild type sequence. Enzymes 
for cloning were purchased from New England Biolabs. Constructs were transferred to E. 
coli BL21(DE3) for expression. All mutations were confirmed by Sanger sequencing 
(Laragen and Retrogen). When necessary, 100 µg mL-1 carbenicillin was included in all 
growth media to maintain selection for the plasmid. To measure the effect of PodA30-162 
on phenazine production in planktonically grown P. aeruginosa, cultures were grown 
overnight in 5 mL volumes of tryptic soy broth (TSB) or succinate minimal medium 
(arginine medium recipe from Glasser et al., 2014 with 40 mM sodium succinate in place 
of arginine) (3) in the presence 1 µg mL-1 PodA30-162. Cells were removed by 
centrifugation and supernatants were analyzed by HPLC as previously described (9). See 
below for a description of biofilm growth of P. aeruginosa PA14. 
 
To induce protein expression, an overnight culture was inoculated 1/1000 in Terrific 
Broth (BD Difco). Cultures were grown in baffled Erlenmeyer flasks (1 L culture per 3 L 
flask) at 37 °C with 150 rpm agitation in a shaking incubator (Innova 44 shaking 
incubator, New Brunswick). After 3-4 hours, the temperature was changed to 16 °C and 
cultures were induced with 50 µM (final concentration) IPTG and left to incubate 
overnight. Cells were then pelleted by centrifugation, flash frozen in liquid N2, and stored 
at −80 °C for up to 1 month before protein purification. 
 
Generation and analysis of phenazines. Pyocyanin (PYO) was purified directly from 
cultures of P. aeruginosa PA14 grown on succinate minimal medium using a previously 
established protocol (31). Briefly, culture supernatants were first extracted with 0.4 
volume dichloromethane (DCM). DCM extracts were treated 1:1 with 0.01 M HCl to 
acidify PYO and extract it back into the aqueous phase. Finally, 1 M NaOH was added to 
pH7, and PYO was extracted back into DCM and dried in vacuo. This crude preparation 
was used for routine analysis of FPLC fractions for activity. To further purify PYO, 
extracts were dried and purified by reverse phase HPLC as described (26, 31). 1-
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hydroxy-phenazine (1-OH-PHZ) was manufactured by TCI America. Phenazine-1-
carboxylic acid (PCA) and phenazine-1-carboxamide (PCN) standards were purchased 
from Princeton Biomolecular Research, Inc. Phenazines from culture supernatants were 
analyzed and measured by HPLC as described previously (6, 9). 
 
Protein extraction and purification. Frozen cell pellets were thawed at room 
temperature and suspended in 25 mL wash buffer (200 mM KCl, 20 mM imidazole, Tris, 
pH 7.6). Cell suspensions were homogenized in an Emulsiflex device (Avestin). Cell 
debris was removed by centrifugation (Avanti J-25 centrifuge, J-series JA-25.50 rotor, 
Beckman-Coulter) at 50,000 xg and supernatant was applied to a nickel GE Healthcare 
HisTrap HP 5 mL nickel column on a GE Healthcare ÄKTAxpress FPLC. All protein 
purification steps were carried out at room temperature. The column with bound protein 
was washed with wash buffer until the UV (280 nm) trace stabilized below 20 mAU. 
Proteins were eluted across a gradient of 20-500 mM imidazole applied over 10 column 
volumes. PYO demethylase activity generally eluted around 300 mM imidazole. Eluted 
protein was concentrated to ~3 mL (Amicon Ultra-15 centrifugal filters, Ultracel 3K 
MWCO) and treated overnight with 1% wt/wt TEV protease (35) while dialyzing 
(Spectra/Por Biotech Dialysis membrane, MWCO: 3.5-5 kD) into buffer containing 200 
mM KCl and 20 mM Tris, pH7.6 at 4 C. Samples were run back through the nickel 
column and PYO demethylase activity was collected in the flow through. Protein was 
concentrated to 250-500 µL (Amicon Ultra – 0.5 mL centrifugal filters, Ultracel – 3K 
MWCO) and loaded on a GE Healthcare HiLoad 16/60 Superdex 200 prep grade gel 
filtration column and run at 1 mL min-1 with gel filtration buffer (100 mM CaCl2, 20 mM 
Tris, pH 7.6). CaCl2 in the buffer was necessary for maximal PodA30-162 activity. Activity 
eluted after ~83 mL. For applications requiring highly purified PodA30-162 (e.g., 
crystallography), an acid precipitation step (400 mM phosphate/citrate, pH 4.2) was 
added either before or after gel filtration chromatography to precipitate trace 
contaminants that were not apparent by SDS-PAGE. PYO demethylase activity remained 
in the supernatant. For acid precipitation, sample was dialyzed into 20 mM Tris, pH 7.6 
between steps to avoid mixing CaCl2 and phosphate buffers. Purified PodA30-162 was 
dialyzed into 20 mM Tris, pH7.6 and stored at 4 °C; protein remained stable with no 
apparent loss of activity for as long as tested (up to 4 months). To determine the 
approximate molecular weight of purified proteins, the elution peak was compared to 
Bio-Rad gel filtration standards run across the same column with gel filtration buffer. 
Mutant proteins were purified on the same day as wild type and fractions where activity 
was seen in wild type were also collected for mutant preparations. Protein quantification 
was carried out by Bradford assay (36) (Quick Start 1x Bradford Dye Reagent, Bio-Rad) 
using pre-diluted Bovine Serum Albumin standards (Thermo Scientific) to establish a 
standard curve. A purification from 6 liters of culture typically yielded 1-2 mg protein. 
Purified proteins were routinely subject to SDS-PAGE using 4-20% Mini-PROTEAN 
TGX precast protein gels (Bio-Rad) and stained with Coomassie Blue. All protein 
preparations were colorless indicating that flavins were not present in the purified 
protein. 
 
Enzyme activity and analysis. PYO demethylation by PodA30-162 was first determined 
by HPLC analysis as described previously (6, 9). To detect formaldehyde evolution, 150 
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nM protein was mixed with 50 µM PYO in 1 mL of 20 mM Tris pH 7.6 amended with 
200 µL Nash reagent (2 M ammonium acetate, 50 mM acetic acid, 20 mM acetylacetone) 
and incubated at 55 °C until the reaction proceeded to completion (37, 38). The products 
were determined by HPLC using the same method as used for phenazine quantification. 
To monitor the formation of reduced phenazine, protein and 50 µM PYO were placed 
into an anaerobic chamber (Coy Laboratory Products) under an atmosphere of H2/N2 
(5:95) and left overnight before allowing the reaction to proceed. To generate reduced 
PYO and 1-OH-PHZ, 50 µM were mixed with 1 mM sodium dithionite. The formation of 
reduced phenazine products was assayed visually under UV illumination (39). A BioTek 
Synergy 4 microplate reader (BioTek) plate reader in the anaerobic chamber was used to 
measure the emission spectrum of products with excitation at 250 nm.  
 
To determine the activity of PodA30-162 in the presence of glycerol, salts, or varying pH, 
30 nM protein was suspended in 500 µL buffer, 40 µM PYO was mixed with 2x solution 
containing the buffer of interest (500 µL), and solutions were preheated to 30 C. For pH 
range measurements, the following buffers were used (40 mM, adjusted with KOH): 
acetic acid, pH 4.9; MES, pH 5.4 and 5.7; HEPES, pH 6.1; Tris, pH 6.9 and 7.5; Bicine, 
pH 7.8, 8.3 and 8.7; CHES, pH 9.4. To measure reaction rates, cuvettes containing the 2x 
PYO solution were placed in a Evolution 260Bio UV-Vis spectrophotometer (Thermo 
Scientific) and 500 µL of 30 nM protein was added at time 0 (15 nM protein and 20 µM 
PYO, final concentration). Reaction progress was monitored by measuring absorbance at 
313 nm (40) every 0.5 seconds for 5 minutes. To measure kinetic parameters (kcat, Km) 15 
nM protein was used in a reaction buffer of Bicine, pH 7.8; reactions were monitored as 
before with measurements every 0.2 seconds. The rate from the first 10 seconds of the 
reaction was used for the determination of kinetic parameters. Kinetic parameters were 
calculated in Microsoft Excel using the Solver plug-in and fitting data to ideal Michaelis-
Menton plots with non-linear regression of experimental data (41). For measurements of 
the rate of methoxy-PMS demethylation, 300 nM protein was used and methoxy-PMS 
loss from the reaction mixture was monitored at 500 nm wavelength. methoxy-PMS was 
purchased from TCI America. For assays with mutant proteins, 60 nM protein was used. 
The stimulatory effects of flavin or 2-oxoglutarate addition was determined by adding 25 
µM flavin or 2-oxoglutarate to 20 µM PYO and 15 nM PodA30-162 and monitoring the 
reaction. 
 
Experiments testing alternative substrates were carried out using in 1 mL reaction 
volumes containing 20 mM Tris (pH 7.6) and 50 µg mL-1 PodA30-162. Alternative 
substrates tested were 10-methylphenothiazine (AlfaAesar), phenazine methosulfate 
(AlfaAesar), methoxyphenazine methosulfate (TCI America), and 4-keto-N-
ethylphenazine. 4-keto-N-ethylphenazine was synthesized from phenazine ethosulfate 
(Sigma-Aldrich) by incubating under fluorescent light overnight followed by purification 
by HPLC as described (6, 42). As phenazine methosulfate is light sensitive and 
spontaneously converts to PYO in the presence of light, all reactions were carried out in 
the dark, and activity was assessed by end point analysis by HPLC after 4 hours (9). 
 
Protein crystallography, X-ray diffraction and analysis. Crystallization screens were 
performed with the JCSG+ screen (Molecular Dimensions) using vapor diffusion in 
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sitting drop format with assistance from the California Institute of Technology Molecular 
Observatory. A Crystal Gryphon liquid-handling robot (Art Robins) was used to mix 0.2 
µL of screen solution with 0.2 µL of protein solution (5 mg mL-1 in 20 mM Tris, pH 7.6 
amended with 200 µM 1-OH-PHZ in DMSO (1% final concentration)). Crystals formed 
in JCSG+ conditions C1, C6, and D12 after 3 days at 20 °C. Varying the salt and polymer 
concentrations in a 24-well plate showed that JSCG+ condition C1 gave robust crystal 
growth in vapor diffusion sitting drop format using 2 µL drops in Micro-Bridges 
(Hampton Research). Protein (5 mg mL-1) was mixed with mother liquor (1µL:1µL) 
composed of 20% w/v PEG 8000, 200 mM NaCl, 200 µM 1-OH-PHZ, 1% DMSO, and 
100 mM sodium phosphate dibasic/citric acid, pH 4.2. Crystals generally formed within 3 
days at 20 °C and were rod shaped with typical dimensions of 50 x 50 x 100 µm. Crystals 
were equilibrated into a cryoprotectant solution (12% w/v PEG 8000, 20% w/v PEG 300, 
100 mM NaCl, 100 µM 1-OH-PHZ, 0.5% DMSO, and 50 mM sodium phosphate 
dibasic/citric acid, pH 4.2) by gradually replacing the sitting drop solution with 
cryoprotectant solution over the span of 10–15 minutes. Crystals were then mounted in a 
nylon loop and flash frozen in liquid nitrogen. 
 
Data collection was performed at 100 K at the Stanford Synchrotron Radiation 
Lightsource (SSRL) beamline 12-2 equipped with a PILATUS 6M Pixel Array Detector. 
X-ray diffraction data were collected at 12,000 eV with a beamstop distance of 32.7 mm 
and a detector distance of 280 nm. Images were collected every 0.15° for a full 360° of 
rotation around a single axis (generating a total of 2400 images). For well-diffracting 
crystals, an additional dataset was collected at 7,000 eV to capture the anomalous signal 
from sulfur and calcium. Diffraction images were integrated and scaled using the XDS 
package (43). To ensure maximum data completion, the two highest quality datasets were 
combined using XSCALE and further processed using POINTLESS, AIMLESS and 
CTRUNCATE in the CCP4 software suite (44-48). The structure was solved by 
molecular replacement in PHASER (49) using a search model derived from a structural 
prediction by Robetta (14-16) with disordered loops trimmed in Coot (50). A preliminary 
model was constructed using phenix.AutoBuild (51) and refined using phenix.refine (52, 
53) and model building in Coot to yield a model with Rfree = 0.22. LigandFit (54, 55) 
analysis in PHENIX (56) was used to model 1-OH-PHZ into the active site of PodA30-162 
with refinement restraints generated using elBOW (simple optimization method) (57). 
The model was modified in Coot to trim side chains with poor electron density coverage. 
A highly coordinated water molecule was identified by phenix.refine as a potential 
calcium atom, presumably originating from the inclusion of 100 mM CaCl2 during the 
final protein purification step. Analysis of the anomalous difference map from a low-
energy dataset supported this identification (Fig. S5) and so the corresponding water 
molecules were replaced with calcium atoms and metal-coordination restraints were 
generated with phenix.metal_coordination via ReadySet!. The final rounds of refinement 
were performed using TLS groups (58) generated by phenix.refine and hydrogen atoms 
set in their riding positions to yield a final model of Rfree = 0.195. Figures were rendered 
with PYMOL version 1.7.2.1, Schrödinger, LLC. 
 
Biofilm experiments. For all experiments involving inactivated PodA, either the E154A 
mutant or PodA30-162 that was subjected to a 1 hour treatment at 98° C was used. To test 
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the ability of PodA30-162 to degrade PYO in the presence of DNA, genomic DNA (gDNA) 
from P. aeruginosa PA14 was used in modified versions of previously described assays 
(59). For experiments using DNA pellets, 0.5 mg of gDNA was pelleted in the presence 
of 300 mM sodium acetate, pH 5.2 and 70% ethanol. Pellets were washed with 70% 
ethanol and dried. 200 µL of 800 µM PYO was added to the gDNA pellet without mixing 
and left to sit at room temperature for 6 hours to allow for diffusion of PYO into the 
gDNA pellet. The pellet was washed once with 70% EtOH, and submerged in a solution 
containing 10 mM Tris, pH 7.0 and 40% isopropanol. The pellet remained blue, 
consistent with an association of PYO with DNA. PodA30-162 was added to the 
isopropanol solution to a final concentration of 2 µg mL-1 and left to sit for 3 hours to 
allow for the reaction to proceed. Tubes were imaged before and after PodA30-162 
treatment. For experiments using solubilized gDNA, a 400 µg mL-1 solution of gDNA 
was mixed with PYO and allowed to equilibrate for 6 hours. The PYO gDNA mixture 
was amended with 1 µg mL-1 PodA30-162 and loss of PYO was monitored on a BioTek 
Synergy 4 microplate reader (BioTek) plate reader at 690 nm. Standards were included to 
quantify PYO loss over time. 
 
To assess biofilm formation in the presence of PodA30-162, biofilms were grown in Nunc 
Lab-Tek chambered coverglass slides (8-well, 0.8 cm2 area, supplier #155411) using a 
modified protocol (22). PA14 was inoculated into succinate minimal medium and grown 
overnight to stationary phase. Cells were resuspended in fresh medium and diluted to a 
starting OD500 of 0.5 in succinate minimal medium. PodA30-162 (2 µg mL-1, final 
concentration) or DNase (20 µg mL-1) (22) was added and 250 µL was added to each 
well of the 8-well chambered coverglass. Cultures were grown for 5 hours at 37 °C and 
100 rpm (Innova 44 shaking incubator, New Brunswick) in a humidified chamber. After 
incubation, liquid was removed from each well by drawing with a pipet tip placed in the 
corner of each well and chambers were washed twice with 400 µL of biofilm wash (Tris 
buffer, pH 7.6 and 100 mM NaCl) to remove planktonic and loosely bound cells. 
Attached biomass was stained by adding 450 µL biofilm wash containing 10 µg mL-1 
DAPI (4’,6-diamidino-2-phenylindole) (Santa Cruz Biotechnology). Surface associated 
biomass was imaged on a Leica TCS SPE confocal microscope with a ACS APO 
40x/1.15 oil immersion objective. A 405 nm solid-state laser was used for excitation, and 
data was collected from 420-500 nm. Images were collected from the same relative 
position in each well along the mid-point of the outer edge on the opposite edge from 
where the washing pipet was placed. Images were collected as 10 µm Z-stacks (10 slices) 
to image the biofilm in its entirety over a surface area of 40,000 µm2. All Z-stacks were 
collected in 8-bit mode with 1024x1024 scan format and a line averaging of 2. A sum 
intensity projection was produced from each Z-stack using ImageJ software (60). Images 
were then thresholded to include pixels with a maximum intensity value >0.15x the 
maximum possible intensity, and thresholded images were used to determine surface 
coverage of each biofilm. Data were collected from 12 biological replicates.  
 
Biofilm aggregate experiments. To test the effect of oxygen limitation in the presence 
of PodA30-162, biofilm aggregates were grown embedded in 0.5% noble agar blocks 
containing succinate minimal medium. Cultures were grown overnight to stationary 
phase in LB, washed once with succinate minimal medium, and resuspended to OD600 
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1.0. Samples were diluted 1:100 in agar at 44°C and 175 µL was transferred to Nunc 
Lab-Tek chambered coverglass slides (8-well, 0.7 cm2 area, supplier #155409). After the 
agar solidified, aggregates were grown for 22 hours in a humidified chamber at 37°C 
before PodA30-162 (2 µg mL-1, final concentration) was added to the top of the agar for an 
additional 5 hours at 37°C. After treatment, 1 µL of stain from ThermoFisher 
LIVE/DEAD BacLight Bacterial Viability Kit in 50 µL ddH2O was added to the top of 
the agar for 12 minutes before microscopic analysis. SYTO-9 from the LIVE/DEAD 
stain kit was used in place of DAPI to minimize background fluorescence. Biomass was 
imaged with a Leica TCS SPE confocal microscope with a ACS APO 10x/0.30 objective. 
A 488 nm solid-state laser was used for excitation, and data was collected from 510-550 
nm. Images were collected across a 500 µm Z-stack with a 10 µm step size. All Z-stacks 
were collected in 8-bit mode with 512x512 scan format and a line averaging of 2. 
Biomass was quantified in ImageJ software (60) by identifying the Z-slice with the 
highest average fluorescent intensity (generally ~200 µm below the agar surface), and 
setting the pixel threshold using the default ImageJ thresholding parameters at the Z-slice 
equivalent to the 100 µm depth. The number of particles in each slice of the Z-stack was 
determined using this threshold value and counting particles >10 µm2 in area. To 
compare biofilm aggregate biomass from different experiments, all Z-stacks were 
normalized by depth so that the Z-slice with the highest average staining intensity was 
considered the mid-point of the 3D reconstruction. This processing allowed for 
comparison of datasets collected on different days with slightly different staining 
intensities and different Z-plane starting coordinates. Particle numbers for each slice were 
averaged between independent experiments and plotted against depth to quantify biofilm 
aggregates. Only experiments with between 400 and 600 aggregates at the plane of peak 
stain intensity were used for averaging and statistical analysis; this ensured equivalent 
biomass was present in each experiment. 
 
Oxygen diffusion modeling. To model oxygen diffusion into agar blocks embedded with 
P. aeruginosa aggregates, we utilized the oxygen diffusion model from (29). Cell 
numbers were estimated by determining the average number of aggregates present and 
calculating the average volume of a given particle with the ImageJ 3D-object counter 
plug-in (61). Given these values, average cell number per mL was estimated by dividing 
the volume of total detected biofilm aggregates by the average volume of a P. aeruginosa 
cell (62) yielding a cell density estimate of 5 x 108. This cell density value is consistent 
with the overnight growth of P. aeruginosa in succinate minimal medium. Oxygen 
diffusion was modeled using this value and 2-fold higher and lower densities to 
encompass a plausible range. 
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Fig. S1. 
PodA30-162 activity is not stimulated by the presence of flavins or 2-oxoglutarate (25 µM) 
in a reaction containing 15 nM PodA30-162. Flavins are known cofactors for many 
demethylases; whereas, several others can utilize 2-oxoglutarate as an electron acceptor. 
 
 
 
9 
 
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
0 10 20 30 µm
ol
es
 P
YO
 d
em
et
hy
la
te
d 
% glycerol 
0 
0.5 
1 
1.5 
2 
2.5 
3 
0 100 200 300 400 µm
ol
es
 P
YO
 d
em
et
hy
la
te
d 
[KCl] µM 
0 
0.5 
1 
1.5 
2 
2.5 
3 
0 100 200 300 400 µm
ol
es
 P
YO
 d
em
et
hy
la
te
d 
[NaCl] µM 
0	
1	
2	
3	
4	
5	
4.5	 5.5	 6.5	 7.5	 8.5	 9.5	
µm
ol
es
	P
YO
	d
em
et
hy
la
te
d	
pH	
0 
0.4 
0.8 
1.2 
1.6 
0 10 20 30 
V 
(µ
m
ol
es
 m
in
-1
) 
[PYO] µM 
A 
B 
C 
D 
E 
 
Fig. S2 
PodA30-162 activity is minimally inhibited by the presence of glycerol (A) or salt (B,C). 
(D) PodA is active over a wide pH range, but loses activity at pH above ~9. Data are 
from duplicate measurements and data was collected for 5 minutes in a reaction mixture 
containing 20 µM PYO and 15 nM PodA30-162. (E) Analysis of PodA30-162 reaction rate, 
V, across a range of PYO concentrations in a reaction containing 15 nM PodA30-162. 
Reaction rates are from data collected during the first 10 seconds after enzyme addition. 
The detection limit of PYO was 0.5 µM; therefore, PYO concentrations below the Km of 
the enzyme were not tested. However, based on the shape of the curve of a best fit to an 
ideal Michaelis-Menton plot, the apparent Km is below 1 µM. Data are from three 
independent protein preparations. Each color represents data from a different protein 
preparation. 
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Fig. S3 
Alternative substrate utilization by PodA. Methylated substrates and their predicted 
demethylated products are shown. Mixtures were analyzed by HPLC (right graphs) after 
4 hours to determine the resulting products of each reaction. Standards for each product 
were run to determine retention times (indicated for each molecule with arrows). Only N-
methylated phenazines were altered by incubation with PodA30-162. 4-keto-N-
ethylphenazine and 10-methylphenothiazine were not demethylated or de-ethylated. 
PMS, phenazine methosulfate. 
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180° 
 
Fig. S4 
Overlay of the Robetta structure prediction model (red) with the initial, solved structure 
of PodA30-162 (Rfree = 0.22 structure described in the methods) (blue). While PodA30-162 
crystallized as a trimer in the asymmetric unit, only the A chain monomer is shown here. 
RMSD of the C-alpha backbone: 2.23 Å vs. Robetta prediction. A version of the Robetta 
prediction model with trimmed loops was used to as the search model for molecular 
replacement (RMSD: 2.11). The N and C terminal extensions on the Robetta prediction 
were not resolved in the electron density of the solved structure. 
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Fig. S5 
Electron density maps of the PodA active site and coordinated calcium ion. (A) Fo-Fc 
map of the missing density for 1-OH-PHZ before ligand modeling and refinement 
(contoured at 3.0 sigma). Only the density within 5 Å of the active site residues is shown 
to highlight the missing ligand density. (B) Zoomed in view of the density around select 
residues in the active site (2Fo-Fc map, blue – contoured at 1.0 sigma). The anomalous 
difference map for the entire monomer is shown (orange map – contoured at 5.0 sigma), 
but density is only apparent around a calcium ion located ~16Å from the bound 
phenazine. Density for the bound 1-OH-PHZ molecules was apparent in each of the three 
subunits. Only the active site of the A chain monomer is shown here. There is no 
apparent density to support the presence of additional cofactors or metal atoms. (C) 
Zoomed in view of the loop containing the coordinated calcium ion. 
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Fig. S6 
(A) Both the C to A (C88A, C102A) and a C to S (C88S, C102S) double mutants show 
activity in cell-free lysates of E. coli BL21(DE3) expressing the protein of interest. While 
activity was always apparent in cell-free lysates, it was unstable and often lost upon 
further purification. (Note: the data for the C to A mutation in panels A-D of Figure 3 are 
from a rare preparation where protein remained active throughout purification.) C to S 
has less apparent activity than C to A, but serves as an independent confirmation of the 
phenotype. Cell lysates of the E154A mutant show that the loss of PYO is not due to an 
activity inherent to E. coli; furthermore, the accumulation of 1-OH-PHZ by both C to A 
and C to S lysates was confirmed by HPLC. (B) Reducing and (C) non-reducing SDS-
PAGE of mutant PodA30-162 proteins. Under reducing conditions, PodA30-162 and mutant 
proteins all have similar migration through SDS-PAGE. Under non-reducing conditions, 
the presence of a disulfide bond leads to slightly faster migration through SDS-PAGE for 
all proteins except the C to A double mutant. 
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Fig. S7 
(A) Dose dependence of PodA30-162 activity in overnight cultures grown in TSB in the 
presence of the indicated amount of enzyme. Enzyme was added at the start of the culture 
and remained stable throughout the incubation period. (B) The phenazine biosynthetic 
pathways of P. aeruginosa (40). There is no known direct route for conversion of PYO or 
1-OH-PHZ to PCA or PCN. Therefore, the response of P. aeruginosa to PodA30-162 
addition in Fig. S8 must be due to active regulatory control of the overall distribution of 
phenazines. 
 
 
15 
 
F
0 
20 
40 
60 
80 
M
 
0 
50 
100 
150 
200 
M
 
untreated PodA PodA-inactive untreated PodA PodA-inactive A B
D
E
0 
100 
200 
300 
400 
µM
 to
ta
l p
he
na
zi
ne
s 
untreated 
PodA 
PodA-inactive 
C
0 
40 
80 
120 
160 
200 
0 30 60 90 120 
PY
O
 (
M
) 
Time (minutes) 
PodA PodA-inactive 
PodA+DNA PodA-inacive+DNA 
PYO PCN 1-OH-PHZ PCA PYO PCN 1-OH-PHZ PCA 
TSB SMM 
bd bd bd
 
Fig. S8 
PodA30-162 alters phenazines in P. aeruginosa culture. PodA30-162 alters phenazine 
concentrations in both TSB (A) and succinate minimal medium (SMM) (B). Data are 
averages from quadruplicate measurements and error bars represent one standard 
deviation around the mean. bd, below detection (< 0.5 µM). (C) Total phenazine 
concentrations in TSB and SSM as summed from panels A and B. While the distribution 
of phenazines is altered by PodA30-162 in TSB, total concentrations remain constant. (D) 
PYO associated with precipitated DNA is not protected from PodA30-162. (E) Inactivated 
PodA30-162 does not demethylate PYO. (F) Solubilized DNA does not block PodA30-162 
activity. 200 µM PYO was incubated in the presence or absence of 400 µg mL-1 DNA (a 
stoichiometric excess). While these data do not preclude the possibility that PYO is 
loosely associated with DNA and may freely dissociate, and PodA may act on this 
solubilized PYO, they do confirm that DNA does not protect PYO from PodA30-162 
activity.  
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Table S1. 
Data collection and refinement statistics for PodA30-162 
Space group P21 21 21 
Cell dimensions        a, b, c (Å) 65.33, 72.98, 79.7 
    α, β, γ (°)  90, 90, 90 
Resolution (Å) 34.98 - 1.8 (1.864  - 1.8) 
Rmerge 0.177 (1.98) 
Rmeas 
Rpim 
CC1/2 
0.180 (2.01) 
0.036 (0.391) 
0.999 (0.827) 
I/s(I) 
Wilson B-factor 
13.3 (2.3) 
24.8 
Completeness 1.00 (1.00) 
Multiplicity 25.9 (26.1) 
No. reflections used in refinement 35987 (3544) 
Rwork / Rfree 0.168(0.271) / 0.195(0.283) 
No. non-hydrogen atoms 2905 
    Macromolecules 2644 
    Ligands 48 
Average B factor 36.5 
    Macromolecules 36.1 
    Ligands 36.4 
    Solvent 42.0 
R.m.s. deviations      Bond lengths (Å) 0.007 
    Bond angles (°) 0.94 
Ramachandran plot statistics (%)      Favored 98 
    Allowed 2.5 
    Outliers 0 
 
Two crystals were used for data collection.  
Values in parentheses are for highest-resolution shell. 
 
 
 
17 
 
Table S2. 
Strains, primers and plasmids used in this study. 
Strain Reference 
    Pseudomonas aeruginosa PA14 (32) 
    P. aeruginosa ∆phz (31) 
    Escherichia coli BL21(DE3) (33) 
    
      Plasmid Description 
    pET20b(+)-podA30-162 podA30-162 expressed from the IPTG inducible promoter of pET-20b(+) 
pET20b(+)-podA30-162, D68A D68A mutant podA30-162 expressed from the IPTG inducible promoter of pET-20b(+) 
pET20b(+)-podA30-162, D72N D72N mutant podA30-162 expressed from the IPTG inducible promoter of pET-20b(+) 
pET20b(+)-podA30-162, C88A,C102A C88A,C102A double mutant podA30-162 expressed from the IPTG inducible promoter of pET-20b(+) 
pET20b(+)-podA30-162, C88S,C102S C88S,C102S double mutant podA30-162 expressed from the IPTG inducible promoter of pET-20b(+) 
pET20b(+)-podA30-162, H121A H121A mutant podA30-162 expressed from the IPTG inducible promoter of pET-20b(+) 
pET20b(+)-podA30-162, E154A E154A mutant podA30-162 expressed from the IPTG inducible promoter of pET-20b(+) 
pET20b(+)-podA30-162, Y156F Y156F mutant podA30-162 expressed from the IPTG inducible promoter of pET-20b(+) 
      Primer Sequence 
    podA30-162-NdeI-F AAAACATATGGACGGTCGCGGCGGCCGGAGTA 
 podA30-162-TEV-Pst-R AAAACTGCAGTCAATGGTGATGGTGATGGTGGCTCTGGAAGTACAGGTTTTCGGCTTTCGTC AGTTTCAATTCGTACTTCTCA 
podA30-162-pET20b-F-NdeI AAAACATATGGACGGTCGCGGCGGCCGGAGTACA 
 podA30-162-pET20b-R-NotI TTTTGCGGCCGCTCAATGGTGATGGTGATGGTGGCT 
 CtoS-F GATAATCCAATGACCTATTCCGAACTGACCATTCACCTCGATGCAGGTGA 
CtoS-R CGGCGTCACATTGGTGAAAAAGGACGCGCCGCCGTCATATCCGACCTGCTTACCGT 
CtoA-F GGATAATCCAATGACCTATGCCGAACTGACCATTCACCTCGATGCAGGTGA 
CtoA-R GGCGTCACATTGGTGAAAAAGGCCGCGCCGCCGTCATATCCGACCTGCTTACCGTCT 
D68A-F GCCATCTTCTCCGACATCCTCTCGGTAGA 
 D68A-R CATGTCTCCGACATCCATACCCGGT 
  H121A-F GCCACACTCGCACCTTTCACCATGGCCA 
 H121A-R CGGGGTGAGGCTACGGGCAAAGATCTCA 
  E154A-F GCGAAGTACGAATTGAAACTGACGAAAGC 
 E154A-R ATCGGGAGTCGCAACACCGGATACGGT 
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